Clinical Trials · NCT03323749
A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension
- Phase
- Phase 3
- Recruitment status
- Terminated
- Sponsor
- Stealth BioTherapeutics Inc.
- Enrollment
- 218
- Start date
- Oct 2017
- Locations
- 27 sites, 7 countries
- Primary endpoint
- Six-minute Walk Test (6MWT)